How to Get a Continuous Glucose Monitor (CGM) Covered by Insurance in 2026: A Step-by-Step Guide

A continuous glucose monitor used to be a device that was almost exclusively covered for people with Type 1 diabetes on multiple daily insulin injections. In 2026 that picture is very different. Medicare has broadened the eligibility rules to include many people with Type 2 diabetes who don't use insulin, commercial insurers have loosened prior authorization criteria to match, and two over-the-counter CGMs are now sold directly to consumers. The result is that a lot more people can get a CGM covered — but the process is still bureaucratic, and roughly two out of three denials come down to missing paperwork rather than genuine ineligibility.

This guide walks through exactly what has changed for 2026, what documentation your prescriber needs to file, how to appeal a denial without hiring anyone, and what to do if coverage is impossible — including the two OTC devices and how they interact with HSA and FSA accounts.

Coverage rules split into three buckets: Medicare, commercial insurance (employer plans and ACA Marketplace plans), and Medicaid. The 2026 rules are more generous than 2025 in all three, but they diverge in the details.

Medicare (Part B, through DME)

Medicare treats CGMs as durable medical equipment. In 2026 you can qualify for Medicare CGM coverage if you have diabetes and any of the following applies: you use insulin (any form, any frequency); you use a daily injectable non-insulin diabetes medication such as a GLP-1 agonist or SGLT2 inhibitor; you have a documented history of problematic hypoglycemia; or you have been hospitalized for a hyperglycemic or hypoglycemic event. Your prescribing clinician must document one of these criteria, and you must have a follow-up visit — in person or by telehealth — within six months of the initial CGM order. Miss that follow-up and Medicare can retroactively terminate coverage.

Commercial insurance

Most commercial plans mirror the Medicare criteria but add prior authorization. The typical 2026 commercial coverage criteria require a diabetes diagnosis (Type 1 or Type 2), documentation of insulin use or hypoglycemia risk, records of prior blood-glucose self-monitoring (usually at least four fingersticks per day), and a treatment plan explaining how the CGM data will be used. Some plans now designate a "preferred" CGM — for example, some plans have made Abbott FreeStyle Libre the preferred device and treat Dexcom G7 as non-formulary. If your plan has a preferred device, either your prescriber picks that one from the start or you'll need to justify why the non-preferred device is medically necessary for your case.

Medicaid

Medicaid CGM coverage is state-by-state and has been expanding rapidly. Most state Medicaid programs now cover CGMs for Type 1 diabetes at any age and for Type 2 diabetes with insulin use or documented hypoglycemia. A growing number cover CGMs for Type 2 diabetes with GLP-1 or SGLT2 therapy. Check your state's specific criteria — the differences are real, and a device that is covered in one state may not be in another.

Even when a CGM is covered, cost varies substantially depending on your plan.

If your plan runs CGMs through the pharmacy benefit — increasingly common in 2026 — the monthly copay is often lower and more predictable than the DME path. Ask your plan's member services whether CGMs are billed under DME or pharmacy, and if there is a choice, pharmacy is usually cheaper for the patient.

This is the order most successful approvals actually follow. Skipping steps is the top reason people wait months for a device.

1. Schedule a visit with the prescriber who manages your diabetes. That's usually your endocrinologist, primary care physician, or an advanced practice clinician who handles your diabetes care. Bring at least two weeks of your current blood glucose logs — or a note explaining why you haven't been able to test.
2. Ask the prescriber to write a Letter of Medical Necessity. The letter should state your diagnosis, your treatment (insulin or GLP-1/SGLT2 name and dose), evidence of glycemic instability or hypoglycemia risk, and how the CGM will be used to adjust therapy. This letter is what determines approval.
3. Confirm which CGM your plan prefers. Call member services or check the online formulary. If the plan has a preferred device, choose it unless there is a specific clinical reason to use a different one.
4. Have the prescriber submit the prior authorization. This goes to the insurer's utilization management team. Ask the prescriber's office for the reference number so you can follow up.
5. Follow up in 5 to 7 business days. Both with the prescriber and the insurer. Prior authorizations get lost. Most decisions come back within 15 days, but active follow-up shortens that.
6. Once approved, pick your supplier. Commercial plans may let you fill at a pharmacy (Walgreens, CVS, and increasingly major retail chains dispense CGMs) or through a DME distributor. Medicare CGMs typically go through Medicare-enrolled DME suppliers or specific mail-order pharmacies.

A denial is not the end of the process. About two thirds of CGM denials happen because of missing or insufficient paperwork, not because the patient truly doesn't qualify. The appeal path is well established and often successful.

Step 1: Get the denial letter and read it carefully

The insurer must send a written denial that names the specific reason. Common reasons include "insufficient documentation of insulin use," "no evidence of frequent self-monitoring," "not medically necessary at this time," or "non-formulary device." Each of these has a different fix.

Step 2: Fix the specific problem

If the denial was for documentation, ask your prescriber to resubmit with the exact records the insurer named — usually more detailed glucose logs, A1C history, or a specific note about hypoglycemia events. If the denial was for a non-formulary device, either switch to the preferred device or have your prescriber write a step-therapy exception explaining why the preferred device is contraindicated for you.

Step 3: File a Level 1 internal appeal

You have to file within your plan's deadline, typically 180 days from the denial. The appeal is a formal written request for the insurer to reconsider. Include a new Letter of Medical Necessity that directly addresses the denial reason, any updated clinical records, and a reference to the plan's own written coverage policy for CGMs. Plans have to respond within 30 days for prospective care and 60 days for retrospective care.

Step 4: Escalate to Level 2, then external review

If Level 1 is denied, most plans have a Level 2 internal appeal. If that is also denied, you have the right under the ACA to an external independent review — a decision by a physician reviewer with no financial tie to your plan. External review overturns commercial denials for CGMs at a meaningful rate, especially when the medical record clearly supports the clinical criteria.

Step 5: If prior authorization was mishandled, use the 2026 CMS rule

The 2026 CMS prior authorization rule (CMS-0057) shortens response deadlines and requires plans to give a specific reason for denials. If your plan blew a deadline or gave a vague reason, that is itself grounds for a complaint to your state insurance department. See our detailed guide on appealing a prior authorization denial under CMS-0057.

Two consumer CGMs are now sold in the United States without a prescription: Dexcom Stelo and Abbott Lingo. A third, Abbott's Libre Rio, was FDA-cleared in 2024 but has not been widely commercially launched. These devices are marketed as wellness products, not medical devices, and they are not billed through insurance under any circumstances in 2026.

Because these devices are marketed as wellness products, they are not subject to the same accuracy standards as prescription CGMs and are labeled for use by people who don't take insulin. That said, the underlying sensor technology is the same, and many patients whose insurance denies a prescription CGM find that Stelo or Lingo is a workable alternative at a lower total cost than fighting the insurer for months.

Both OTC CGMs are HSA and FSA eligible. Prescription CGMs qualify automatically; OTC CGMs typically qualify but some HSA/FSA administrators may ask for a letter of medical necessity from your provider — a short letter is usually enough. Save your receipts.

Prediabetes

Insurance almost never covers a CGM for prediabetes in 2026. Some employer wellness programs are beginning to subsidize OTC CGMs for prediabetic employees; check your benefits portal. Otherwise, the OTC route is your only path.

Gestational diabetes

Coverage for gestational diabetes is expanding but inconsistent. Insulin-treated gestational diabetes generally qualifies; diet-controlled gestational diabetes typically does not. If you are denied and your obstetrician thinks CGM is important, an appeal citing hypoglycemia risk during pregnancy has a reasonable chance of success.

Medicare Advantage vs. Original Medicare

Medicare Advantage plans must cover everything Original Medicare covers, but they can impose their own prior authorization and preferred device rules. If you are considering switching from Medicare Advantage back to Original Medicare specifically to access a broader CGM supplier network, see our Medicare Advantage-to-Original switching guide.

Losing coverage mid-supply

If you lose your job or your plan changes and your CGM prior authorization no longer applies, the new plan will require its own prior authorization. Order what you can while the old approval is still active and start the new plan's process immediately — CGM sensor gaps are stressful, but plan transitions are common enough that most prescribers know how to expedite.

If you want to get a CGM covered in 2026, work through this list in order:

1. Confirm you meet the 2026 clinical criteria for your payer — insulin, GLP-1/SGLT2, hypoglycemia history, or hospitalization.
2. Book a visit with your prescriber and bring at least two weeks of blood glucose logs.
3. Get a Letter of Medical Necessity that maps directly to your plan's coverage policy.
4. Call member services to confirm the plan's preferred device and whether CGMs are billed under DME or pharmacy.
5. Have the prescriber submit the prior authorization and get the reference number.
6. Follow up in a week with both the prescriber and the insurer.
7. If denied, request the written denial, fix the specific issue, and file a Level 1 appeal within the deadline.
8. Escalate to external review if internal appeals fail — this is where a lot of well-documented denials get overturned.
9. If coverage is truly not possible, evaluate Stelo or Lingo through your HSA or FSA.

The 2026 rules opened the door for millions of people who couldn't get a CGM covered a year ago. The paperwork hasn't gotten simpler — but the coverage criteria have gotten more forgiving, and the appeal path is well worn. If you meet the clinical criteria and your prescriber submits complete documentation, approval is the norm, not the exception. And if the insurer still won't budge, the OTC market has finally caught up to the point where paying out of pocket is not a financial catastrophe.